Cover Image
市場調查報告書

C5a過敏毒素趨化受體1 (C5a過敏毒素趨化受體,C5a-R,CD88,C5AR1):開發中產品分析

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363563
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
C5a過敏毒素趨化受體1 (C5a過敏毒素趨化受體,C5a-R,CD88,C5AR1):開發中產品分析 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 57 Pages
簡介

本報告提供全球各國的C5a過敏毒素趨化受體1 (或C5a過敏毒素趨化受體、C5a-R、CD88、C5AR1) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • C5a過敏毒素趨化受體1 (C5a過敏毒素趨化受體,C5a-R,CD88,C5AR1)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AFFiRiS AG
    • ChemoCentryx, Inc.
    • Dompe Farmaceutici S.p.A.
    • Noxxon Pharma AG
  • 藥物簡介
    • CCX-168
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • DF-2593A
    • 牙周病的C5aR拮抗劑
    • EP-67
    • NOXD-19
    • NOXD-20
    • 未公開症狀的C5aR標的小分子
    • 肌肉萎縮性側索硬化症(ALS) 的C5aR拮抗用合成肽
    • 老年癡呆症的C5a標的疫苗
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0609TDB

Summary

Global Markets Direct's, 'C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016', provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6
  • Therapeutics Development 7
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Stage of Development 7
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Therapy Area 8
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Indication 9
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Products Glance 10
  • Late Stage Products 10
  • Early Stage Products 11
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Companies 12
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Universities/Institutes 14
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment 16
  • Assessment by Monotherapy/Combination Products 16
  • Assessment by Mechanism of Action 17
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 20
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development 22
  • AFFiRiS AG 22
  • ChemoCentryx, Inc. 23
  • Dompe Farmaceutici S.p.A. 24
  • Prommune, Inc. 25
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles 26
  • avacopan - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • DF-2593A - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • Drug to Antagonize C5aR for Periodontitis - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • EP-67 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Vaccine to Target C5a for Alzheimer's Disease - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Projects 37
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products 39
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Featured News & Press Releases 40
  • Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 40
  • Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 40
  • Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 42
  • May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 43
  • Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 45
  • Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 46
  • Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 47
  • Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 48
  • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 49
  • Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 49
  • Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 50
  • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 51
  • Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 51
  • Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 52
  • Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease 54
  • Appendix 56
  • Methodology 56
  • Coverage 56
  • Secondary Research 56
  • Primary Research 56
  • Expert Panel Validation 56
  • Contact Us 56
  • Disclaimer 57

List of Tables

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Late Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Number of Products under Development by Companies, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Number of Products under Investigation by Universities/Institutes, H2 2016 14
  • Products under Investigation by Universities/Institutes, H2 2016 15
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Stage and Mechanism of Action, H2 2016 18
  • Number of Products by Stage and Route of Administration, H2 2016 19
  • Number of Products by Stage and Molecule Type, H2 2016 21
  • Pipeline by AFFiRiS AG, H2 2016 22
  • Pipeline by ChemoCentryx, Inc., H2 2016 23
  • Pipeline by Dompe Farmaceutici S.p.A., H2 2016 24
  • Pipeline by Prommune, Inc., H2 2016 25
  • Dormant Projects, H2 2016 37
  • Dormant Projects (Contd..1), H2 2016 38
  • Discontinued Products, H2 2016 39

List of Figures

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Top 10 Indication, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Mechanism of Actions, H2 2016 17
  • Number of Products by Stage and Mechanism of Actions, H2 2016 17
  • Number of Products by Stage and Routes of Administration, H2 2016 19
  • Number of Products by Molecule Types, H2 2016 20
  • Number of Products by Stage and Molecule Type, H2 2016 20
Back to Top